Eric Shen

675 total citations
29 papers, 428 citations indexed

About

Eric Shen is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Oncology. According to data from OpenAlex, Eric Shen has authored 29 papers receiving a total of 428 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 4 papers in Cardiology and Cardiovascular Medicine and 4 papers in Oncology. Recurrent topics in Eric Shen's work include Pulmonary Hypertension Research and Treatments (20 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (13 papers) and Medical Imaging and Pathology Studies (5 papers). Eric Shen is often cited by papers focused on Pulmonary Hypertension Research and Treatments (20 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (13 papers) and Medical Imaging and Pathology Studies (5 papers). Eric Shen collaborates with scholars based in United States, United Kingdom and Germany. Eric Shen's co-authors include Heber MacMahon, Steven D. Nathan, Paul A. Brown, Aaron B. Waxman, Jeffrey M. Isner, Peter Smith, Victor F. Tapson, Andrew C. Nelsen, C. Q. Deng and Amy Hajari Case and has published in prestigious journals such as Gastroenterology, American Journal of Respiratory and Critical Care Medicine and CHEST Journal.

In The Last Decade

Eric Shen

27 papers receiving 413 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric Shen United States 11 354 103 97 63 46 29 428
Nikolaos Galanakis Greece 12 247 0.7× 134 1.3× 138 1.4× 35 0.6× 35 0.8× 47 395
Olivier Raffy France 7 198 0.6× 78 0.8× 80 0.8× 32 0.5× 35 0.8× 13 260
David Amar United States 10 263 0.7× 68 0.7× 121 1.2× 24 0.4× 24 0.5× 18 343
Sandra Lombardi United States 9 269 0.8× 41 0.4× 191 2.0× 32 0.5× 15 0.3× 14 361
Gülten Taçoy Türkiye 12 111 0.3× 101 1.0× 253 2.6× 31 0.5× 39 0.8× 53 359
Eisaku Ito Japan 12 242 0.7× 232 2.3× 66 0.7× 26 0.4× 10 0.2× 63 377
B. de Latour France 10 183 0.5× 105 1.0× 22 0.2× 18 0.3× 23 0.5× 24 266
Sven Janssen Netherlands 9 73 0.2× 56 0.5× 79 0.8× 44 0.7× 55 1.2× 12 357
Julie Guest United States 5 157 0.4× 111 1.1× 66 0.7× 12 0.2× 21 0.5× 8 291

Countries citing papers authored by Eric Shen

Since Specialization
Citations

This map shows the geographic impact of Eric Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Shen more than expected).

Fields of papers citing papers by Eric Shen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Shen. The network helps show where Eric Shen may publish in the future.

Co-authorship network of co-authors of Eric Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Eric Shen. A scholar is included among the top collaborators of Eric Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric Shen. Eric Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
White, R. James, Karim El‐Kersh, Stephan Rosenkranz, et al.. (2024). Treatment With Oral or Inhaled Treprostinil in Patients With Pulmonary Arterial Hypertension and Cardiovascular Comorbidities. CHEST Journal. 167(6). 1746–1758. 1 indexed citations
3.
Weatherald, Jason, Steven D. Nathan, Karim El‐Kersh, et al.. (2024). Inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease with less severe haemodynamics: a post hoc analysis of the INCREASE study. BMJ Open Respiratory Research. 11(1). e002116–e002116. 7 indexed citations
4.
Franco, Verónica, Vijay Balasubramanian, Ronald Zolty, et al.. (2023). Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil. Respiratory Medicine. 218. 107374–107374. 3 indexed citations
5.
Nathan, Steven D., Shilpa Johri, Christopher S. King, et al.. (2023). Survival analysis from the INCREASE study in PH-ILD: evaluating the impact of treatment crossover on overall mortality. Thorax. 79(4). 301–306. 12 indexed citations
6.
Waxman, Aaron B., Ricardo Restrepo‐Jaramillo, Thenappan Thenappan, et al.. (2023). Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study. European Respiratory Journal. 61(6). 2202414–2202414. 32 indexed citations
7.
Argula, Rahul, Shelley Shapiro, Karim El‐Kersh, et al.. (2023). The impact of comorbidities on inhaled treprostinil treatment in patients with pulmonary arterial hypertension. PA1203–PA1203. 1 indexed citations
8.
9.
Nathan, Steven D., C. Q. Deng, Christopher S. King, et al.. (2022). Inhaled Treprostinil Dosage in Pulmonary Hypertension Associated With Interstitial Lung Disease and Its Effects on Clinical Outcomes. CHEST Journal. 163(2). 398–406. 22 indexed citations
10.
Nathan, Steven D., Victor F. Tapson, Jean Elwing, et al.. (2021). Efficacy of Inhaled Treprostinil on Multiple Disease Progression Events in Patients with Pulmonary Hypertension due to Parenchymal Lung Disease in the INCREASE Trial. American Journal of Respiratory and Critical Care Medicine. 205(2). 198–207. 44 indexed citations
11.
Nathan, Steven D., Aaron B. Waxman, Sudarshan Rajagopal, et al.. (2021). Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. The Lancet Respiratory Medicine. 9(11). 1266–1274. 88 indexed citations
12.
Shapiro, Shelley, Ricardo Restrepo‐Jaramillo, Eric Shen, et al.. (2021). Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54 µg (nine breaths) four times daily. Pulmonary Circulation. 11(4). 1–7. 5 indexed citations
13.
Nathan, Steven D., Victor F. Tapson, Gautam Ramani, et al.. (2021). COMPARISON OF EFFECTS OF INHALED TREPROSTINIL ON LUNG FUNCTION IN PATIENTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE AND PULMONARY ARTERIAL HYPERTENSION. CHEST Journal. 160(4). A2244–A2246. 2 indexed citations
14.
Kovács, Gábor, Horst Olschewski, Meredith Broderick, et al.. (2021). Combination Therapy in Pulmonary Arterial Hypertension—Targeting the Nitric Oxide and Prostacyclin Pathways. Journal of Cardiovascular Pharmacology and Therapeutics. 26(5). 453–462. 19 indexed citations
15.
Mordin, Margaret, et al.. (2019). The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension. Lung. 198(1). 65–86. 10 indexed citations
16.
17.
18.
Isner, Jeffrey M., et al.. (1984). Sudden unexpected death as a result of anomalous origin of the right coronary artery from the left sinus of Valsalva. The American Journal of Medicine. 76(1). 155–158. 62 indexed citations
19.
Shen, Eric, et al.. (1982). [Coronary arteriographic findigs among Chinese patients in Hong Kong].. PubMed. 21(5). 285–7. 1 indexed citations
20.
Shen, Eric, et al.. (1964). [THE DESCENDING PATHWAYS OF THE BULBAR CARDIOVASCULAR CENTER].. PubMed. 27. 108–14. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nikolaos Galanakis Breakdown of academic impact, for papers by Olivier Raffy Breakdown of academic impact, for papers by David Amar Breakdown of academic impact, for papers by Sandra Lombardi Breakdown of academic impact, for papers by Gülten Taçoy Breakdown of academic impact, for papers by Eisaku Ito Breakdown of academic impact, for papers by B. de Latour Breakdown of academic impact, for papers by Sven Janssen Breakdown of academic impact, for papers by Julie Guest
Rankless by CCL
2026